SAN DIEGO--(BUSINESS WIRE)--Impact Biomedicines today announced that retrospective data on fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor that is being developed initially for the treatment of myelofibrosis (MF) and polycythemia vera (PV), will be presented in a poster at the 59th American Society of Hematology (ASH) Annual Meeting, taking place on December 9-12, 2017 in Atlanta, GA.
The details of the presentation are as follows:
Session: 634 – Myeloproliferative Syndromes: Clinical: Poster III
Poster
Title: Case Series of Potential Wernicke’s Encephalopathy in
Patients treated with Fedratinib
Presenter: John Hood, Ph.D.
Date:
Monday, December 11, 2017
Presentation time: 6:00-8:00 PM ET
Location:
Georgia World Congress Center, Bldg A, Lvl 1, Hall A2
About Impact Biomedicines
Impact Biomedicines (“Impact”) is pioneering the development of life changing treatments for patients with complex cancers. The Company’s pipeline is centered around fedratinib, a potent and highly selective oral small molecule, JAK2 kinase inhibitor that is being developed initially for the treatment of myelofibrosis (MF) and polycythemia vera (PV).